Detalhe da pesquisa
1.
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Nature
; 620(7976): 1063-1070, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587335
2.
A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq.
Genomics
; 116(2): 110793, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38220132
3.
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
Br J Cancer
; 127(3): 488-499, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35501389
4.
Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Blood
; 135(13): 1019-1031, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978211
5.
DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa.
Mol Cell
; 48(3): 343-52, 2012 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23000175
6.
Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death.
Genes Dev
; 24(15): 1608-13, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20679396
7.
Plasmacytomagenesis in Eµ-v-abl transgenic mice is accelerated when apoptosis is restrained.
Blood
; 124(7): 1099-109, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24986687
8.
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
Blood
; 121(12): 2285-8, 2013 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23341542
9.
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Blood
; 119(24): 5807-16, 2012 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22538851
10.
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell
; 10(5): 389-99, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17097561
11.
The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
Nat Genet
; 37(9): 953-7, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16116421
12.
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis.
Cell Death Differ
; 30(4): 1018-1032, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36755068
13.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ther Adv Med Oncol
; 15: 17588359231208674, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38028140
14.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
medRxiv
; 2023 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36993400
15.
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
J Exp Clin Cancer Res
; 42(1): 112, 2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37143137
16.
Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
Blood
; 116(17): 3197-207, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20631380
17.
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.
Blood
; 116(24): 5256-67, 2010 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-20829369
18.
Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation.
Blood
; 115(2): 344-52, 2010 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965665
19.
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
Front Genet
; 13: 886170, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36159999
20.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Cancer Res
; 82(23): 4457-4473, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206301